Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.
BIRC5
Core Binding Factor (CBF)
acute myeloid leukaemia
inv(16)
overall survival
survivin
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
13
09
2021
accepted:
22
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Despite recent advances in therapies including immunotherapy, patients with acute myeloid leukaemia (AML) still experience relatively poor survival rates. The Inhibition of Apoptosis (IAP) family member, survivin, also known by its gene and protein name, Baculoviral IAP Repeat Containing 5 (BIRC5), remains one of the most frequently expressed antigens across AML subtypes. To better understand its potential to act as a target for immunotherapy and a biomarker for AML survival, we examined the protein and pathways that BIRC5 interacts with using the Kyoto Encyclopedia of Genes and Genomes (KEGG), search tool for recurring instances of neighbouring genes (STRING), WEB-based Gene Set Analysis Toolkit, Bloodspot and performed a comprehensive literature review. We then analysed data from gene expression studies. These included 312 AML samples in the Microarray Innovations In Leukemia (MILE) dataset. We found a trend between above median levels of BIRC5 being associated with improved overall survival (OS) but this did not reach statistical significance (
Identifiants
pubmed: 34638823
pii: ijms221910482
doi: 10.3390/ijms221910482
pmc: PMC8508831
pii:
doi:
Substances chimiques
BIRC5 protein, human
0
Neoplasm Proteins
0
Survivin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Blood Cancer J. 2020 Oct 30;10(10):107
pubmed: 33127875
Blood. 2009 Jan 29;113(5):1203-4
pubmed: 19179477
Blood Rev. 2019 Jul;36:70-87
pubmed: 31101526
Cell Cycle. 2014;13(6):984-91
pubmed: 24552823
Clin Cancer Res. 2008 Nov 15;14(22):7161-6
pubmed: 19010831
Blood. 2003 Jul 15;102(2):462-9
pubmed: 12649129
Oncogene. 2002 Mar 27;21(13):2051-7
pubmed: 11960377
Blood. 2008 Feb 1;111(3):1357-65
pubmed: 17978170
J Biol Chem. 2003 Jun 20;278(25):23130-40
pubmed: 12660240
Am J Hematol. 2011 Nov;86(11):918-22
pubmed: 21898529
Dis Markers. 2021 Jul 26;2021:5511041
pubmed: 34354775
Biochem Pharmacol. 2014 Jul 1;90(1):16-24
pubmed: 24735609
Cancer Res. 1998 Dec 1;58(23):5315-20
pubmed: 9850056
Blood Rev. 2017 Jan;31(1):63-76
pubmed: 27639498
Br J Haematol. 2008 Jan;140(2):250-1
pubmed: 18028484
Blood. 2002 May 15;99(10):3517-23
pubmed: 11986202
Cell. 2006 Nov 3;127(3):539-52
pubmed: 17081976
Cancer Sci. 2019 Aug;110(8):2378-2385
pubmed: 31218770
BMC Cancer. 2013 Jan 02;13:1
pubmed: 23282137
Nucleic Acids Res. 2019 Jan 8;47(D1):D881-D885
pubmed: 30395307
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Hematol Oncol. 2010 Mar;28(1):13-9
pubmed: 20013787
Blood. 2009 Jul 9;114(2):394-403
pubmed: 19411632
Nature. 1998 Dec 10;396(6711):580-4
pubmed: 9859993
Oncogene. 2004 Apr 12;23(16):2825-37
pubmed: 15077146
J Natl Cancer Inst. 2014 Jan;106(1):djt356
pubmed: 24309006
Cancers (Basel). 2021 May 04;13(9):
pubmed: 34064473
Blood. 2008 May 1;111(9):4490-5
pubmed: 18309032
J Cell Biol. 2006 Jun 19;173(6):833-7
pubmed: 16769825
J Clin Oncol. 2010 May 20;28(15):2529-37
pubmed: 20406941
Cancer Lett. 2006 Dec 8;244(2):164-71
pubmed: 16621243
Biochemistry. 2001 Jan 30;40(4):1117-23
pubmed: 11170436
Oncogene. 2004 Oct 21;23(49):8146-53
pubmed: 15361831
BMC Cancer. 2017 Dec 28;17(1):889
pubmed: 29282022
Cancer Cell Int. 2016 Jun 23;16:49
pubmed: 27340370
Blood. 2005 Aug 1;106(3):938-45
pubmed: 15827130
Cancers (Basel). 2020 Sep 27;12(10):
pubmed: 32992503
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Oncogene. 2000 Jul 6;19(29):3225-34
pubmed: 10918579
Nat Rev Cancer. 2008 Jan;8(1):61-70
pubmed: 18075512
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
BMC Cancer. 2021 Apr 17;21(1):424
pubmed: 33863308
Int J Hematol Oncol Stem Cell Res. 2017 Oct 1;11(4):328-339
pubmed: 29340131
Sci Rep. 2020 Feb 24;10(1):3250
pubmed: 32094363
Exp Hematol. 2008 Nov;36(11):1449-60
pubmed: 18687517
J Cell Sci. 2008 Apr 1;121(Pt 7):925-32
pubmed: 18354082
Blood. 2009 Apr 23;113(17):4052-62
pubmed: 19144991
Blood. 2006 Dec 15;108(13):4109-17
pubmed: 16931630
J Clin Invest. 2015 Jan;125(1):157-68
pubmed: 25415440
J Exp Clin Cancer Res. 2019 Aug 22;38(1):368
pubmed: 31439015
J Cell Sci. 2019 Apr 4;132(7):
pubmed: 30948431
Oncotarget. 2017 Dec 17;9(3):3853-3866
pubmed: 29423088
Blood. 2007 Aug 15;110(4):1291-300
pubmed: 17485551
Cell Cycle. 2006 Feb;5(3):296-303
pubmed: 16418575
J Cell Mol Med. 2009 Aug;13(8B):2039-2052
pubmed: 19602047
Oncogene. 2002 Apr 18;21(17):2613-22
pubmed: 11965534
N Engl J Med. 2004 Apr 15;350(16):1605-16
pubmed: 15084693
Cancer Lett. 2015 Oct 1;366(2):160-72
pubmed: 26123662
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
J Biol Chem. 2002 Feb 1;277(5):3247-57
pubmed: 11714700
Cancer. 2016 Oct;122(19):3005-3014
pubmed: 27315441